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AbsTrACT
Liver biopsy is required when clinically important 
information about the diagnosis, prognosis or 
management of a patient cannot be obtained by 
safer means, or for research purposes. There are 
several approaches to liver biopsy but predominantly 
percutaneous or transvenous approaches are used. A 
wide choice of needles is available and the approach 
and type of needle used will depend on the clinical 
state of the patient and local expertise but, for non- 
lesional biopsies, a 16- gauge needle is recommended. 
Many patients with liver disease will have abnormal 
laboratory coagulation tests or receive anticoagulation 
or antiplatelet medication. A greater understanding 
of the changes in haemostasis in liver disease allows 
for a more rational, evidence- based approach to peri- 
biopsy management. Overall, liver biopsy is safe but 
there is a small morbidity and a very small mortality so 
patients must be fully counselled. The specimen must 
be of sufficient size for histopathological interpretation. 
Communication with the histopathologist, with access 
to relevant clinical information and the results of other 
investigations, is essential for the generation of a 
clinically useful report.
ExECuTivE summAry
Histopathological interpretation of a liver biopsy is 
indicated when information for diagnosis, manage-
ment, treatment or prognostication is not avail-
able from non- invasive techniques. Liver biopsy is 
also indicated for research purposes where there is 
appropriate ethics approval and consent.
Patient consent should be obtained prior to the 
biopsy. Information provided should include the 
benefits and risks of liver biopsy, alternatives where 
appropriate, and follow- up arrangements. The 
information should be given verbally and supple-
mented with written information in a format that 
is understandable by the patient and, where appro-
priate, their carers. Where possible, this informa-
tion should be given several days before the biopsy 
by a healthcare practitioner who is familiar with the 
techniques and with enough time for the patient to 
ask questions. Consent should be confirmed imme-
diately prior to the biopsy.
Risks of percutaneous liver biopsy include 
bleeding, organ perforation, sepsis and death. 
Bleeding occurs in up to 10% with major bleeding 
occurring in less than 2%. Risk factors for bleeding 
from percutaneous biopsy include older age, comor-
bidities, indication for biopsy and coagulation. 
There is little conclusive evidence that operator 
status and number of passes significantly affects the 
risk of bleeding. Mortality associated with biopsy is 
less than 1 in 1000.
Haematological parameters in many patients 
with liver disease are abnormal, with disturbance of 
both thrombolysis and coagulation; the traditional 
measures of platelet count and prothrombin time 
do not give an accurate reflection of the coagula-
tion status of the patient. It is recommended that for 
non- lesional biopsies, in patients with liver disease, a 
transvenous route should be used if the international 
normalised ratio (INR) is >1.4. For percutaneous 
lesional biopsies, the INR should be <2.0. There is 
no evidence that fresh frozen plasma is effective in 
reducing bleeding and is not recommended.
Most liver biopsies are obtained by radiologists, 
but there is little clear evidence that this is associated 
with reduced complications or increase in adequate 
samples.
Although there is little convincing evidence that 
obtaining percutaneous liver biopsy under imaging 
guidance reduces complications, we recommend 
that where possible, liver biopsy should be obtained 
under ultrasound guidance; where this is not appro-
priate, we recommend that the liver should have 
been imaged within 3 months of the biopsy (or more 
recently if there has been any change in the condi-
tion of the patient) to enable planning of the optimal 
biopsy site.
We recommend the use of automated cutting- type 
needles and that full core biopsy needles are used, 
provided that the operator is sufficiently experienced 
in the use of these needles. We recommend that a 
16 G needle should be used for the percutaneous 
approach, although an 18 G needle should be used 
for percutaneous biopsy of a solid lesion, and the 
length of the sample should be at least 20 mm.
There should be clear communication between 
the clinician requesting the biopsy, the person 
obtaining the biopsy and the histopathologist gener-
ating the report. The request form should include 
2 Neuberger J, et al. Gut 2020;0:1–22. doi:10.1136/gutjnl-2020-321299
Guidelines
the indication(s) and all relevant clinical and other information to 
ensure that the procedure is done as safely as possible and that 
the histopathologist has all the necessary information. The biopsy 
report should clearly deal with the clinical indication(s) for the 
biopsy and conclude with a concise diagnostic summary. The 
report should be given in a timely fashion. For biopsies obtained 
outside a specialist liver centre, the reporting pathologist should 
have access to a second opinion from a liver centre.
research and audit questions
In many aspects of liver biopsy, the evidence is weak. We recom-
mend that there should be local and national audits for the major 
complications of liver biopsy; these should include evaluation of 
the various types of liver biopsy needle used to provide evidence 
for the safest and most effective needle units, and clinicians under-
taking liver biopsies should ensure their own and centre’s compli-
cation rates are within accepted range; we recommend that there 
should be national standards, evidence- based where possible, about 
the training and competencies of those obtaining liver biopsies; we 
recommend that there is further research into the haematological 
parameters that preclude safe percutaneous biopsies and into inter-
ventions to reduce the risk of bleeding after liver biopsy
LivEr biopsy GuidELinEs: pATiEnT/LAy summAry
A fuller lay summary is given in online supplementary material.
introduction
A liver biopsy is a diagnostic test, which involves the removal of 
a small quantity of tissue from the liver, usually done under local 
anaesthetic, to allow microscopic examination of the liver.
purpose of a liver biopsy
There are many causes of liver disease and it is sometimes diffi-
cult to diagnose and work out the best treatment using other 
tests such as non- invasive imaging techniques or blood tests.
The main reasons for a liver biopsy are to
 ► help clarify diagnosis;
 ► determine severity of liver damage or grade of tumour;
 ► help predict prognosis in a person with a known diagnosis;
 ► inform treatment decisions;
 ► monitor disease progression or response to treatment;
 ► obtain liver tissue for non- histological assessment (microbi-
ology, biochemical, other);
 ► support research.
meeting patient concerns
Some patients are anxious about having a biopsy, are unsure 
what it involves or why they have to have it, how long it takes or 
how much it is likely to hurt. The British Liver Trust has identi-
fied three key areas for improvement: communication, consent 
and post- biopsy information.
risks of having a biopsy
Generally, liver biopsy is a safe procedure, but it is not free of 
risk. All invasive procedures have an associated risk of illness or 
disease (morbidity) or death (mortality). The reported risk of 
complications varies depending on the type of biopsy.
The risk of a biopsy needs to be balanced against the benefits 
that the findings of a biopsy will provide. The development of 
complications is not necessarily the fault or error of the health-
care professional. Some situations are associated with increased 
risk, such as where there is infection or obstruction in the liver or 
bile ducts, ascites (fluid in the abdomen) or pregnancy.
Complications
Complications are uncommon but there may be some mild pain 
or discomfort in the area of the biopsy. In a small number of 
cases there is some minor bleeding that soon stops.
After a biopsy, patients should seek medical advice when:
 ► Bleeding occurs from the site of the biopsy.
 ► The biopsy site becomes red, angry looking or swollen.
 ► A high temperature (fever) develops.
 ► The biopsy site is still painful after a few days and painkillers 
do not help.
In more severe and rarer cases, a blood transfusion and/or an 
operation is required to deal with the bleeding. On occasion it is 
possible for bile to leak from the liver internally. There is a small 
risk that the small wound will become infected after the biopsy.
different techniques for undertaking a liver biopsy
There are various approaches to obtaining a liver biopsy.
Percutaneous liver biopsy
Percutaneous liver biopsy is the most common type of biopsy. It 
involves inserting a thin needle through the skin into the liver 
and removing a small piece of tissue. Before the procedure, you 
will be asked to lie on your back or on your left side. The skin 
over the liver region is then cleaned and prepared by applying 
antiseptic. Some local anaesthetic is then injected into a small 
area of skin and tissues just over a part of the liver (usually 
between two lower ribs on the right- hand side) to make the skin 
in this area numb. A special hollow needle is inserted through 
your skin into the liver. The clinician will ask you to breathe 
in and then out and then hold your breath while the needle is 
inserted into the liver. The needle will remove a small sample of 
liver tissue for further examination. The clinician obtaining the 
biopsy may be guided by an ultrasound scanner or CT scan for 
greater accuracy. Such scans are painless. Imaging can potentially 
reduce the risk of complications. Contrast- enhanced ultrasound 
may be of use in those with advanced chronic liver disease.1
A blind liver biopsy is where the biopsy is done without 
imaging guidance. The guidelines state that a blind liver biopsy 
should not be performed without recent liver imaging (within 
the preceding 3 months) and this imaging should be reviewed 
before undertaking a biopsy.
Transvenous/transjugular biopsy
A transvenous/transjugular biopsy is used in patients who have 
difficulty with blood clotting where there is a risk of bleeding.
You will be asked to lie on your back and the radiologist will 
apply a numbing medication on one side of the neck and makes a 
small incision. They then insert a flexible hollow tube (catheter) 
into the jugular vein. A contrast dye is then injected into the 
tube and a series of images taken. The dye allows the specialist 
to see the hepatic vein. A biopsy needle is then threaded through 
the tube and one or more liver samples are taken. The catheter 
is carefully removed, and the incision covered with a bandage.
Other types of liver biopsy include transfemoral (using the 
femoral vein as access point), endoscopic ultrasound- guided 
liver biopsy (done through an endoscope in the duodenum) and 
laparoscopic liver biopsy (through the abdomen, either during 
an operation or through a laparoscope).
What care should you receive after your liver biopsy?
Biopsies are usually done on the day and do not necessitate 
an overnight stay. You are expected to lie on your side and are 
observed for at least 3 hours to check there is no further bleeding. 
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Any pain or discomfort experienced can usually be treated with 
painkillers.
The report may take 2 weeks or so to come back but if special 
tests are required, may be longer
informed consent
Consent should be obtained from all patients prior to a liver 
biopsy in accordance with national guidelines. Consent must 
be voluntary, informed and the patient must have the mental 
capacity to decide. Information should be given orally and 
supplemented in written form using language that is comprehen-
sible. The patient should be aware, in advance, of the benefits 
and risks of the procedure.
Where a biopsy is undertaken solely or partly for research 
purposes, patients must be fully informed and the procedure 
approved by the appropriate ethics committee/body in align-
ment with hospital regulations.
monitoring after the liver biopsy
Patients are monitored so pain can be treated appropriately, and 
any complications detected and attended to early.
Discharge should happen only if your condition is stable—
that is, when your circulation is acceptable/stable, there is no 
evidence of bleeding, blood pressure is normal and you do not 
have complaints of pain or shortness of breath.
Prior to discharge, you should be given oral and written 
instructions regarding further monitoring and day to day activi-
ties. This should include advice to rest and not drive motor vehi-
cles, not to operate heavy machinery, not undertake strenuous 
activity or lift heavy objects for 48 hours.
If you experience any symptoms that would suggest discom-
fort, infection or injury, you should be instructed to contact the 
hospital and be provided with contact details how to do this.
What happens to the sample after the liver biopsy?
After the liver biopsy the sample is sent to a laboratory where 
it is assessed by a pathologist. It may take 2 weeks or more to 
obtain the report.
Samples from liver biopsies should be stored for 30 years. 
Reviewing biopsies over time can inform how the liver disease 
is progressing.
professional responsibility
The decision to undertake a biopsy involves a number of clini-
cians with different specialist skills. You should have confidence 
that the decision to undertake a biopsy is correct and that the 
risks are carefully assessed.
All members of the team involved in the clinical decision- 
making should be aware of the risks and benefits in each 
individual case. Serious complications must be recorded and 
monitored.
Much clearer guidance on the competencies required and the 
training needed to undertake a liver biopsy should be developed.
Quality standards
For non- urgent biopsies, the interval between request and biopsy 
should be less than 4 weeks, regardless of which type of proce-
dure is adopted.
All patients should be given oral and written information 
about the indications, benefits and risks of biopsy together with 
details of post- discharge support.
inTroduCTion And bACkGround
Current guidance
The previous British Society of Gastroenterology (BSG) guide-
lines on the use of liver biopsy in clinical practice were published 
in 19992 and modified in 2004.3 Since that time, there have 
been many advances in the diagnosis, investigation and manage-
ment of liver diseases. With the advent of newer serological 
and imaging techniques, the indications for liver biopsy have 
changed. Furthermore, as detailed in the section on 'Current 
practice', there have been changes in who does the liver biopsy, 
the needles available and use of imaging. There have also been 
advances in the development of new drugs for control of clotting 
and platelet function and greater understanding of the processes 
of haemostasis in liver disease. Therefore, it was agreed that the 
time was right for a complete review of the guidelines.
objective of guidance
The objective of these revised guidelines is to provide healthcare 
professionals and patients clear recommendations on the role of 
liver biopsy in clinical adult practice.
development of guidelines
The guidelines were developed under the auspices of the BSG 
and in lines with the BSG and National Institute for Health 
and Care Excellence (NICE) recommendations, following 
the Appraisal of Guidelines for Registration and Evaluation 
(AGREE) II .4 5 Because these guidelines affect several groups of 
healthcare professionals, they were developed in collaboration 
with the Royal College of Pathologists and the Royal College 
of RadiologistsThe group met on five occasions, and developed 
the content and agreed electronically. Individual members led 
the development of each section, using search terms including 
liver biopsy, histology, guidelines, blood coagulation disorders, 
haematological tests, bleeding risk assessment, coagulopathy, 
platelet function assay 100 (PFA-100), thromboelastogram, 
rotational thromboelastography (ROTEM), post- biopsy haem-
orrhage/bleed, invasive procedure, interventional radiology, 
biopsy, percutaneous. The guidelines have been reviewed by 
members of the liver section of the BSG. The final guidelines 
have been approved by all members of the guideline committee.
Assessing the quality of guidelines
The AGREE II instrument is an accepted method for appraising 
clinical guidelines. Six domains are listed.
Scope and purpose
The guidelines are intended for use by clinicians and other health-
care professionals, who may refer a patient for liver biopsy, who 
may obtain a liver biopsy, interpret the liver histology and care 
for the patient during and after the procedure. Guidance on liver 
biopsy was published by the BSG in 2004 and by the American 
Association for the Study of Liver Disease in 2009.6
Guideline Development Group (GDG) membership and stakeholder 
involvement
Because these guidelines affect several groups of healthcare 
professionals, they were developed in collaboration with the 
Royal College of Pathologists, the Royal College of Radiol-
ogists and reviewed by the British Society of Haematology. 
Membership of the group includes gastroenterologists, hepa-
tologists, interventional radiologists, histopathologists, nursing 
and patient representation. The guideline has been reviewed and 
ratified by the BSG liver section committee, the British Society 
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Table 1 Levels of evidence
Certainty interpretation
Very low The true effect is probably markedly different from the estimated 
effect
Low The true effect might be markedly different from the estimated effect
Moderate The authors believe that the true effect is probably close to the 
estimated effect
High The authors have a lot of confidence that the true effect is similar to 
the estimated effect
box 1 purposes of liver biopsy
Help clarify diagnosis
Determine severity of liver damage
Determine the nature and/or grade of tumour
Help predict prognosis in a person with a known diagnosis
Inform treatment decisions
Monitor disease progression or response to treatment
Obtain liver for non- histological assessment (microbiology, 
biochemical, other)
Support research
of Gastroenterology, the Royal College of Radiologists and the 
Royal College of Pathologists.
Rigour of development
The published literature has been searched using PubMed, 
Medline, Web of Knowledge and the Cochrane database until 
February 2020. The GDG had a series of teleconferences and 
meetings and agreed revisions electronically. Individual members 
led on the development of each section, using search terms 
including liver biopsy, histology, guidelines, blood coagula-
tion disorders, haematological tests, bleeding risk assessment, 
coagulopathy, PFA-100, thromboelastogram, ROTEM, post- 
biopsy haemorrhage/bleed, invasive procedure, interventional 
radiology, biopsy, percutaneous.
In accordance with the BSG advice on production of guide-
lines, the GDG applied the GRADE (Grading of Recommenda-
tions, Assessment, Development and Evaluations) system. Our 
grading of evidence was based on four levels of evidence and the 
strength of our recommendation (high, moderate, low or very 
low) (table 1). Areas of disagreement about the recommendation 
grade were discussed and, if necessary, voting by members of 
the guidelines group, although this was rarely required. Where 
possible, the health benefits, side effects and risks of recommen-
dations have been discussed.
Clarity and presentation
Key recommendations are linked to discussion threads on a 
discussion forum hosted on the BSG website.
Applicability
Where necessary, we have discussed organisational changes that 
may be needed in order to apply recommendations. We have 
attempted to identify key criteria for monitoring and audit 
purposes.
Editorial independence and conflict of interest
Guideline group members have declared any conflicts of interest.
CurrEnT prACTiCE
Clinical care
Following recent improvements in non- invasive tests, the indi-
cations for liver biopsy have decreased, although histology still 
remains invaluable in diagnosis and management of selected 
patients.7 There is no consensus on best practice.
The UK guidelines issued by the BSG were revised in 2004.2 3 
Since then, there have been advances in technology that allow non- 
invasive assessment of the liver, better understanding of the clot-
ting of blood and further information about the safety and risks 
of different needles. Review of practice around the UK (unpub-
lished) suggests that the great majority of biopsies are obtained by 
radiologists under ultrasound guidance, but in a few centres some 
biopsies are still done on the ward without concurrent ultrasound 
guidance. There is considerable variation in many areas, such as 
the information given to patients, where the procedure is done, 
the haematological parameters allowing safe percutaneous biopsy, 
the competence required to do the biopsy, in the reporting of liver 
pathology and in professional accountability. An audit of the first 
50 liver biopsies done in UK centres after 1 January 2008 showed 
that, of the 87 departments who responded, liver biopsy was done 
mainly by the radiologist (consultant 76%, trainee 19%, radiogra-
pher <1%), gastroenterologist (consultant 1%, trainee 3%), other 
(1%).8
The patient perspective
More work needs to be done to make the approach to liver 
biopsy completely patient facing. Patients have much anxiety 
about the procedure, often with a lack of understanding of what 
is involved, how long it takes and how much it may hurt. In 
2017–2018, of the 1807 liver health enquiries received by the 
British Liver Trust helpline services, 23 were related specifically 
to liver biopsies. The online support community forum has been 
operational since 2012, and more than 3500 posts have discussed 
liver biopsies. Recently, the British Liver Trust reviewed the help-
line services enquiries, liaised with their support group facilitator 
and collated feedback regarding commonly expressed concerns 
relating to their experience of liver biopsy. Three main areas of 
concern were identified:
1. Communication: Patients report clinicians saying they ‘need-
ed a liver biopsy’ but not explaining why or discussing any 
alternative medical investigations.
2. Consent: Patients highlighted the importance of being giv-
en enough time to discuss the indications fully, alternatives, 
risks and benefits of liver biopsy as part of the consent pro-
cedure in a safe, quiet area, prior to the procedure taking 
place. Where possible, this should not be on the same day 
as the procedure and patients should have an opportunity to 
discuss any concerns (with healthcare professionals and with 
relatives and friends) and have time to come back with any 
questions and queries. Patients also expressed a need for the 
consent to be taken by a healthcare professional who was 
knowledgeable about liver biopsies.
3. Postprocedure care: Patients often reported being given little 
or no discharge information after the procedure, especially 
about pain, what analgesia to take and when/where to seek 
medical help, if needed.
indiCATions for LivEr biopsy
Liver biopsy is usually done in one of two situations: for the 
assessment of diffuse liver disease or to diagnose a specific 
abnormality seen on cross- sectional imaging using a targeted 
biopsy. The purposes of a liver biopsy are outlined in box 1.
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Table 2 Recommended interval for discontinuation of antiplatelet and anticoagulant medication prior to liver biopsy
drug dose stop notes
Clopidogrel, prasugrel, ticagrelor 7 Days If cannot delay for 7 days stop clopidogrel for 
24 hours; platelet transfusion may be used but 
transjugular liver biopsy route is recommended
Aspirin 3–7 Days prior to elective procedures For urgent biopsies, aspirin can be continued at the 
discretion of the clinician
Dual antiplatelet therapy—for example, 
aspirin/clopidogrel
Consider if biopsy can be delayed or if 
clopidogrel can be stopped.
Always continue aspirin
Many patients receiving this antiplatelet combination 
have cardiac stents
Dipyridamole Omit on day of biopsy
Low molecular weight heparin Prophylactic dose 12 Hours before procedure
Higher than prophylactic dose 24 Hours before procedure
Direct oral anticoagulants Omit for 2 days before procedure Omit for longer if dabigatran and renal impairment
Non- invasive methods to aid clinical decisions are preferred 
by patients rather than liver biopsy.9 With current virological, 
biochemical, serological and imaging investigations, many diag-
noses and management decisions do not rely on histological 
information. As the indications for liver biopsy change, clinical 
teams need to ensure the decision to biopsy remains appropriate. 
Indications for liver biopsy in many conditions is outlined in 
specific guidelines. For disease- specific indications, see online 
supplementary appendix A.
A liver biopsy done for clinical (rather than research) purposes, 
can be justified only when
 ► The information gained is of value for management of the 
patient.
 ► The patient is fully informed about indications, risks, bene-
fits, alternatives and follow- up plans and has given informed 
consent.
 ► The procedure is done as safely as practicable.
 ► The operator is competent to perform the technique.
 ► The sample(s) are of adequate quality and size.
 ► The biopsy is examined by a histopathologist sufficiently 
competent to interpret the histology.
The operator and the histopathologist must be given all the 
relevant information, and the histopathologist should have 
access to a specialist referral pathway for unusual or complex 
biopsies, including post- transplant biopsies.10 These topics are 
discussed in detail below.
Recommendations
 ► All healthcare professionals involved in requesting, obtaining 
and interpreting the liver biopsy need to be aware of the 
indication(s) for the biopsy (strength of recommendation 
STRONG; quality of evidence WEAK).
 ► Where a biopsy is done outside guidelines or protocols, 
there should be multiprofessional discussions (which should 
include histopathologists where appropriate) prior to biopsy, 
and the decision recorded in the medical notes (strength of 
recommendation STRONG; quality of evidence WEAK).
CLiniCAL siTuATions WiTh inCrEAsEd risk of 
LivEr biopsy (ExCLudinG hAEmAToLoGiCAL issuEs/
ConsidErATions)
Many contraindications to percutaneous liver biopsy are relative 
and were defined when different techniques and larger diameter 
needles were used.
The uncooperative patient
Patients may be unable to cooperate for a variety of reasons, 
including anxiety. During the process of obtaining a percutaneous 
liver biopsy, it is essential that the patient is cooperative as any 
untoward movement when the biopsy needle is in the hepatic 
parenchyma can lead to a tear of the liver and capsule, with subse-
quent significant bleeding and pain. If the patient is anxious, then 
sedation with midazolam can be considered, with no increased 
risk.11 General anaesthesia can be used when the risks are justified.
Extrahepatic biliary obstruction
Extrahepatic biliary obstruction is frequently stated to be a 
contraindication to liver biopsy because of the risks of biliary 
peritonitis, septicaemic shock and death.12 In one study, serious 
complications occurred in at least 2% of patients (including 
biliary peritonitis), and another study reported significant 
complications in 4% following percutaneous liver biopsy.13 With 
current imaging techniques (specifically, magnetic resonance 
cholangiopancreatography and endoscopic retrograde pancrea-
tography), liver biopsy should be done for biliary obstruction 
only when there is doubt about the diagnosis and the benefit to 
the patient outweighs the risk.14
Where the biliary tree is dilated, a transjugular approach 
should be used because of the risks of biliary leak.
bacterial cholangitis
The risk of inducing peritonitis and septic shock after liver 
biopsy has made cholangitis a relative contraindication. Bacter-
aemia after percutaneous biopsy of a non- infected liver occurs in 
up to 14% of biopsies.15 16
Ascites
Percutaneous biopsy of the liver in the presence of large volume 
ascites is considered a contraindication in many texts. The reasons 
for this vary and include technical challenges and the risk of uncon-
trollable bleeding into the ascites; however, the evidence for these 
concerns is weak. CT or ultrasound- guided liver biopsy in the pres-
ence of ascites does not seem to affect the complication rate.17 18
Notwithstanding these studies, if a liver biopsy is clinically 
indicated in a patient with large- volume ascites, an image- guided 
percutaneous biopsy following total paracentesis or a transjug-
ular biopsy can be considered.
Amyloidosis
Because of early reports of haemorrhage and death of patients 
following liver biopsy,19 amyloidosis is often listed as a contra-
indication.20 One case series from 1961 showed an intraperi-
toneal bleed with conservative treatment in 1 of 18 patients.21 
Current publications estimate the mortality of a liver biopsy in 
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patients with amyloidosis at up to 5%.22 However, in patients 
who have had a liver biopsy for investigation of abnormal liver 
tests and who were unexpectedly found to have amyloidosis, the 
mortality and complication rate is lower than generally quoted. 
Since almost all patients with clinically significant liver amyloi-
dosis have hepatomegaly and are of AL type, absence of serum 
and urine monoclonal immunoglobulins and serum light free 
chains makes such a diagnosis very unlikely.
If amyloidosis is strongly suspected, the diagnosis should be 
made by subcutaneous fat or rectal biopsy since most cases of 
amyloid are systemic. However, if suspicion is low and in hepato-
megaly of uncertain aetiology, a liver biopsy can be justified, and 
we recommend the transjugular route.
obesity
In the obese patient, it may be difficult to identify the liver by 
percussion. In this situation, the biopsy should be done under 
ultrasound guidance and in many cases the transjugular route 
might be preferable.
pregnancy
Liver histology is rarely required in the management of the preg-
nant patient but may be helpful in the diagnosis of new onset liver 
abnormalities.23 In one small study, there was a small increased 
risk of premature birth, but no stillbirth was reported.24 In some 
non- life- threatening clinical conditions, it may be reasonable to 
wait until delivery of the baby. Thus, the benefits of biopsy need 
to be balanced against the risks to the mother and baby.
focal lesions with a cystic element
Modern imaging techniques can often identify and categorise 
benign cystic lesions of the liver. Focal liver lesions with a cystic 
element may communicate with several structures, including the 
biliary tree, increasing the risk of biliary peritonitis after biopsy. 
Diagnostic fine needle aspiration may be used to evaluate these 
lesions.25–28 In the biopsy of focal lesions, risks may be increased 
if the lesion is highly vascular: the degree of risk will depend on 
whether the solid element of the lesion can be accessed without 
going through the cyst with the needle. Thus, the risk:benefit 
ratio will depend on the characteristics of the lesion.
Recommendation
 ► Where possible, risks should be minimised (such as seda-
tion, drainage of ascites, biliary decompression) but biopsy 
is justified when the risks are outweighed by the bene-
fits (strength of recommendation MODERATE; quality of 
evidence MODERATE).
TEChniQuEs And proCEdurAL ConsidErATions for 
LivEr biopsy
There are several methods by which a liver biopsy may be 
obtained, classified according to the access site for obtaining the 
biopsy.
operator and operator experience
Historically, gastroenterologists or hepatologists obtained most 
liver biopsies, as a 'blind' procedure. With the increasing use of 
imaging to help obtain percutaneous liver biopsies (PLBs), most 
biopsies are obtained by radiologists or gastroenterologists who 
have adequate training with use of ultrasound scanning (USS) 
assistance or guidance. With more recent expansion of skills, 
other groups of operators, such as clinical nurse specialists and 
physician assistants, have become adept at carrying out liver biop-
sies. It is worth noting that, in the UK and some other countries, 
training in obtaining a liver biopsy is not a requirement for 
training in gastroenterology and hepatology, although training 
should include an understanding of the indications, procedures, 
benefits and risk.29 In the USA, training in liver biopsy is not a 
requirement for level 1 training in hepatology but is a mandatory 
part of the formal advanced training process.30
No randomised trials have explored the impact of operator 
experience on outcome of liver biopsies. Non- randomised 
studies have highlighted the importance of operator experience 
to improve safety and success of liver biopsy, although this has 
not always been shown, but studies have been relatively small.31 
Although there is no defined minimum number, the 1991 BSG 
audit recorded a higher, though not significant, complication 
rate of 3.2% in operators who had performed fewer than 20 
liver biopsies compared with 1.1% in operators who had 
performed >100 liver biopsies.32 Other large published series 
have demonstrated similar findings, suggesting operator experi-
ence improves the quality of sample obtained.33–36 These studies 
emphasise the importance of carrying out a high volume of 
liver biopsy procedures, supervised by an experienced operator, 
before embarking on the procedure unsupervised, irrespective of 
the clinical background of the operator.
Recommendation
 ► Hospital policies should include a formal process and 
governance framework to ensure an operator is suitably 
experienced to undertake liver biopsies independently 
(strength of recommendation STRONG; evidence HIGH).
percutaneous liver biopsy
Percutaneous liver biopsy refers to a biopsy taken by inserting 
a needle directly through the skin into the liver parenchyma. 
This method of biopsy always breaches the liver capsule with the 
attendant risk of intraperitoneal bleeding. Classification is based 
on whether image guidance is used and whether the biopsy track 
is plugged at the end of the procedure.
Typically, a PLB can be done safely in a procedure room on 
a ward, in the imaging department or, when clinically neces-
sary, by the bedside (portable). It is vital that the room is a clean 
environment suitable for undertaking minor procedures and has 
easy access to consumables required for performing the biopsy 
(procedure packs, biopsy needles, etc). If ultrasound guidance 
is being used, the procedure room should be able to house the 
ultrasound machine and have the facility to reduce the ambient 
lighting.
There should be access to interventional radiology services, on 
site or through formalised transfer pathways to a referral centre, 
in the event of haemorrhage requiring embolisation.
Transthoracic and transabdominal liver biopsy
For both these approaches the patient lies supine. The borders 
of the liver are usually defined by percussion or visualised by 
ultrasound, with the breath held in deep expiration. In most 
instances, the intercostal space in the mid- axillary line, midway 
between the dome and tip of the liver, is infiltrated with local 
anaesthetic and a tiny incision is made through the skin. Higher 
(more cephalad) punctures increase the risk of pneumothorax, 
whereas lower punctures increase the risk of non- target organ 
puncture (which may be associated with more risk to the patient). 
The biopsy needle is advanced into the chosen intercostal space 
immediately above the more inferior rib, to avoid injury to the 
intercostal neurovascular bundle. The patient again holds their 
breath in expiration. The needle is advanced towards the xiphis-
ternum, parallel to the bed/table to reduce the risk of injury to 
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the gall bladder or kidney. The subsequent procedure for taking 
the biopsy then varies according to whether the biopsy needle 
is of the aspiration or cutting type and according to the specific 
instructions for use for the individual device. After the biopsy 
procedure, the patient usually lies on their right- hand side or 
supine for a period of time and regular observation of pulse and 
blood pressure are made in order to detect complications early 
(see section 'Clinical considerations').
Blind, ultrasound-assisted and image-guided liver biopsy
The method of liver biopsy described in the section 'Transtho-
racic and transabdominal lover biopsy' is done without USS and 
is commonly referred to as a ‘blind’ biopsy. However, some form 
of contemporary imaging should be available and reviewed to 
ensure there are no anatomical variations or interposing struc-
tures that would affect the chosen skin entry point. Imaging, 
usually with US, can be used to assist identification of the optimal 
site for needle insertion immediately prior to the liver biopsy (US 
assisted) and also detect the presence of new onset ascites. The 
imaging can also be used in real time, usually with US or CT, to 
visualise and guide the needle to the optimal point for biopsy 
(image guided).
Truly blind PLBs have been reducing in number across the UK. 
There are still units where clinicians prefer blind PLB to image 
guidance. Depending on the skills and experience of the operator, 
blind PLB can be safe and effective in obtaining tissue samples.37 38
Use of imaging
A randomised study demonstrated the safety of ultrasound assis-
tance over a blind PLB,39 with similar findings from a retrospec-
tive study.40 However, another retrospective comparative study 
did not demonstrate any benefit in US- guided PLB compared with 
blind PLB.41 Ultrasound assistance can change the skin entry site 
chosen by the percussion method in up to 15% of procedures to 
avoid adjacent structures and identify a safe needle trajectory,42 
thereby reducing both minor and major complications of liver 
biopsy, and increase diagnostic yield.43 However, there is no way 
of predicting cases that might selectively benefit from the use 
of USS.44 It is also not clear whether real- time ultrasound guid-
ance further improves diagnostic yield or reduces complications 
compared with US assistance for non- targeted liver biopsy.45 
Studies based on an economic analysis of the use of US have 
shown cost savings compared with blind PLB after taking into 
consideration the cost of treating complications.46 47
In the biopsy of focal liver lesions, image guidance, with either 
real time US, CT or MRI, is a necessity to place the needle accu-
rately at the site of the lesion and obtain a relevant sample with 
a high degree of accuracy.48 Real- time US has also been used in 
conjunction with fusion imaging to enable successful biopsy of 
focal lesions not readily visible on B- mode ultrasound.49
If operators wish to do ‘blind biopsies’, we recommend that 
this is done only when an ultrasound has been done to exclude 
anatomical and other variants that may affect the optimal site 
for liver biopsy. There are no data from which the maximum 
safe interval can be deduced; we recommend that the interval 
between imaging the liver and obtaining a blind biopsy should 
be no more than 3 months, unless there has been a significant, 
relevant change in the patient’s clinical state which indicates the 
need for more recent imaging.
 ► Recommendations
 ► Where possible, every unit offering PLB should use image 
assistance or image guidance to minimise complications 
(strength of recommendation STRONG; evidence WEAK).
 ► A blind liver biopsy should not be performed in the absence 
of any prior imaging of the liver and only then when a blind 
approach is justified by clinical or logistical reasons (strength 
of recommendation STRONG; evidence WEAK).
 ► Recent liver imaging (within the preceding 3 months in a 
patient with stable liver disease) should be available and 
reviewed prior to performing a blind liver biopsy (strength 
of recommendation; STRONG; evidence WEAK).
 ► Ultrasound assistance should be used to reduce the risk of 
complications of liver biopsy (strength of recommendation 
MODERATE; evidence WEAK).
 ► Image- guided liver biopsies should be used for targeting 
focal lesions or in patients with altered liver anatomy (such 
as split liver graft or prior liver resection) (strength of recom-
mendation STRONG; quality of evidence WEAK).
Choice of biopsy needle
The liver specimen may be taken using either an aspiration 
needle (such as Menghini or Jamshidi) or cutting needle (Tru- 
cut type). The latter are needles with a side notch against which 
the liver tissue sits before an outer sheath cuts the liver spec-
imen. Although traditionally manual biopsy needle systems 
were used, there is more general use of cutting biopsy needle 
guns with an automated firing sequence. More recently, biopsy 
devices which extract a full core of tissue the whole diam-
eter and length of the needle have become available (full core 
biopsy needles).
With regard to needle type, a large study of 68 276 percutaneous 
liver biopsies recorded a higher frequency of complications with a 
Tru- cut needle (3/1000) than the Menghini needle (1/1000).50 It 
was also noted that haemorrhagic complications were seen only 
in patients with malignant disease and cirrhosis. This suggests 
that haemostasis post- biopsy is a multifactorial process, with 
the 'tamponade' effect of the liver parenchyma being at least as 
important as needle type or size. Animal studies have demonstrated 
more bleeding with larger needle gauge,51 but this has not been 
replicated in randomised human studies.52 53 Moreover, larger 
gauge needles provide biopsy samples that are more technically 
adequate and have better diagnostic accuracy, with no significant 
increase in complications.54–56 Findings of another study in 1192 
patients suggested that the sample adequacy of Tru- cut needles was 
superior to that of Menghini needles, with no significant difference 
in complication rates.57 A recent publication showed the superi-
ority of the Biopince 16 G needle compared with the Achieve 
18 G needle, with inadequate biopsies obtained in 2% and 48%, 
respectively.58
The introduction of the full core biopsy needle has allowed a 
higher percentage of technically adequate samples to be obtained 
compared with traditional cutting needles of similar gauge, 
reducing the need for repeat biopsies, with similar complication 
rates.59 60
Recommendation
 ► We recommend use of automated cutting type needles 
However, familiarity with the device should also be taken 
into consideration when choosing the needle (strength of 
recommendation MODERATE; evidence WEAK).
Needle gauge and number of passes
Studies have clearly demonstrated improved diagnostic yield 
with an increased number of needle passes. However, three or 
more passes significantly increased the risk of complications and 
morbidity.61–63 No association was seen between the number 
of passes and severity of complications in at least two large 
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studies.64 65 Factors associated with severe complications were 
patient age, hepatic malignancy and elevated INR.
All the common medical liver diseases have an inherent hetero-
geneity in the distribution of the histological features that are 
required to establish a diagnosis and to assess disease severity. The 
resultant sampling variability may therefore limit the accuracy of 
histological assessments, particularly if the sample obtained is 
small or fragmented. To ensure that the sample is representa-
tive, various studies have suggested that longer sample size, and 
consequentially, increased number of visualised complete portal 
tracts (CPTs), strongly influences eventual diagnosis and staging 
of liver disease.64 66–70 In 2014, the Royal College of Patholo-
gists updated guidelines suggested minimum adequacy require-
ment for samples to be at least 10 mm long and containing six 
portal tracts. However, there is good evidence that the disease 
severity (both fibrosis stage and grade of inflammation) tends to 
be underestimated in biopsies that include fewer than 11 portal 
tracts per tissue section. To obtain an intact core with sufficient 
tissue, the current recommendation is for a biopsy of a minimum 
length of 20 mm, obtained with a 16- gauge needle.10 71 Assess-
ment of shorter biopsies may be compromised, and an additional 
pass should be considered if the sample obtained by the first 
pass is less than 10 mm in length, or is between 10 and 20 mm 
in length if the purpose of the biopsy is to establish the fibrosis 
stage or investigate biliary disease.
This recommendation was supported in the American Associ-
ation for the Study of Liver Diseases (AASLD) position paper.6 A 
retrospective study demonstrated a significantly higher number 
of portal tracts obtained with a 1.6 mm Menghini needle than 
with a 1.4 mm needle.55 This view was supported by other 
retrospective studies that compared different needle sizes.72–74 
The wider biopsy sample also allows better characterisation of 
the relationship between portal tracts, which are about 0.8 mm 
apart (see section 'Pathological considerations'). However, one 
systematic review found poor correlation between sample size 
and number of CPTs.75 Studies comparing 16 G and 18 G Tru- 
cut biopsy needles have suggested improved biopsy samples 
with the larger gauge needles with a larger number of CPTs.53 76 
No doubt, partial core biopsy needles further reduce the actual 
width of tissue obtained due to the side notch, and theoretically 
a similar gauge full core biopsy needle should provide a wider 
sample with more visualised portal tracts. This was demon-
strated in a retrospective comparative study with better samples 
and greater number of portal tracts in a 16 G full core needle 
versus an 18 G partial core needle.58 Further, there is concern 
about potential complications from increased number of passes 
to obtain adequate samples. However, this may be overcome by 
a full core biopsy with a long throw (eg, 30 mm), which could 
provide an adequate sample in a single pass. No comparative 
studies have been identified between full core biopsy needles of 
different sizes.
Recommendations
 ► We recommend one pass for the biopsy unless the diagnostic 
yield is likely to produce insufficient material for a full histo-
logical examination (as outlined in the section 'Pathological 
considerations') (strength of recommendation MODERATE; 
evidence WEAK).
 ► We recommend that broader gauge, full core biopsy needles, 
wider than 18 G, should be used (if the operator has suffi-
cient experience with the needle) for non- lesional indi-
cations (strength of recommendation STRONG; evidence 
MODERATE).
Prophylactic antibiotics
Evidence on the benefit of routine antibiotic prophylaxis for 
biopsies obtained from native or transplanted livers in patients 
with normal biliary anatomy is limited. At least two previous 
studies demonstrated that PLB is associated with a transient 
bacteraemia in 5–13% of cases.15 16 However, no clear evidence 
is available on the proportion of these that develop infective 
complications. One randomised study did not demonstrate any 
significant difference in infective complications in the groups 
with and without prophylactic antibiotics, and the study did not 
recommend routine antibiotic prophylaxis before PLB.77
Slightly more evidence is available in patients undergoing 
liver biopsy in the presence of a biliary- enteric anastomosis. The 
results of these studies are mixed, with no clear consensus. At 
least two retrospective series demonstrate significantly greater 
infective complications following PLB in transplant livers with 
biliary- enteric anastomosis, thus recommending routine antibi-
otic prophylaxis.78 79 At least two case–control studies around 
the same time reported findings to the contrary in patients with 
biliary- enteric anastomosis.80 81 Another case- controlled study 
suggested that infective risk was higher in biliary- enteric anasto-
mosis only in the presence of overt or occult biliary obstruction/
stasis.82
No randomised trials have been published to provide more 
conclusive evidence regarding routine antibiotic prophylaxis in 
PLB in either native or transplanted livers.
Recommendation
 ► Antibiotic prophylaxis should not be used routinely prior 
to PLB except in the presence of a biliary- enteric anasto-
mosis or history of previous post- biopsy infective complica-
tions or in overt biliary sepsis (strength of recommendation 
MODERATE; evidence WEAK).
Plugged liver biopsy
Plugged liver biopsy is a modification of the percutaneous 
approach, first described in 1984.83 It has been advocated as 
an alternative method for obtaining liver tissue in patients with 
impaired coagulation or ascites where transjugular liver biopsy 
(TJLB) is not feasible, such as targeted biopsy of a focal liver 
lesion, or where appropriate facilities are not available. The 
technique involves placing a coaxial introducer needle within the 
liver under ultrasound guidance. The inner trocar is removed, 
and the biopsy is taken through the introducer using a cutting 
needle. Multiple needle passes can be made with only a single 
capsular puncture. The biopsy track is then plugged using gela-
tine sponge or another suitable agent, while withdrawing the 
introducer. It should be noted that the use of a plugged biopsy 
technique requires insertion of an introducer with an inner 
lumen the same gauge as the biopsy needle, thereby creating a 
hole in the liver capsule of a greater size than the biopsy needle 
itself. No randomised trials of PLBs and plugged PLBs are avail-
able to determine the benefit of tract plugging in the presence of 
impaired coagulation.
Since the original description of the technique, multiple retro-
spective studies have highlighted the safety of plugged liver 
biopsy using a variety of agents, such as gelatine sponge,84 85 
fibrin sealant,86 cyanoacrylate glue87 or blood products such as 
fresh frozen plasma.88 There have been no randomised trials to 
demonstrate superiority of one plugging agent over another.
One randomised controlled trial involving 100 patients 
demonstrated that plugged PLB was quicker to perform, 
provided larger samples but had a marginally higher, though 
non- significant, risk of haemorrhage after biopsy than TJLB.89 
9Neuberger J, et al. Gut 2020;0:1–22. doi:10.1136/gutjnl-2020-321299
Guidelines
A more recent retrospective comparative study also suggested 
slightly lower technical success rates using TJLB than with 
plugged biopsy, and TJLB was associated with a lower average 
core length and lower average number of specimens obtained, 
but both methods yielded sufficient tissue for a definitive diag-
nosis. No major complications occurred in either group.90
Transvenous liver biopsy
Disorders of coagulation and/or ascites are common in patients 
with liver disease. Under these circumstances, conventional 
percutaneous liver biopsy would be contraindicated because of 
the perceived increased haemorrhagic risk. A transvenous route 
provides an alternative approach to liver biopsy, which poten-
tially avoids breach of the liver capsule and reduces the risk of 
bleeding.
A transvenous biopsy requires the use of fluoroscopic guid-
ance and needs to be performed in an angiography suite in the 
interventional radiology department. Inherently, these rooms are 
clean environments, often theatre grade, suited for performing 
such invasive angiographic procedures.
Transjugular liver biopsy
A TJLB is the favoured transvenous approach when a percuta-
neous liver biopsy is contraindicated or when additional inves-
tigations such as hepatic venography or hepatic vein pressure 
studies are also required. As with percutaneous biopsies, needles 
in TJLB sets are either of the aspiration type or cutting type. 
Previous cross- sectional or ultrasound imaging is usually suffi-
cient prior to TJLB in providing information about patency of 
hepatic veins and their anatomical relations. The procedure is 
performed with ECG monitoring because of the risk of arrhyth-
mias as the right atrium is traversed. Internal jugular venous 
(IJV) access (preferentially on the right side) is gained under 
ultrasound guidance. The right hepatic vein is normally cathe-
terised and a long sheath advanced into the hepatic vein. The 
appropriate biopsy set and needle are then placed in the mid- 
portion of the hepatic vein. To obtain the specimen, the whole 
system, once in the right hepatic vein, is rotated anteriorly and 
medially. The needle tip is then advanced a few millimetres 
beyond the sheath tip and the biopsy taken by either advancing 
the aspiration needle further into the liver parenchyma or firing 
the automated cutting needle. Specimens tend to be smaller and 
more fragmented than those obtained through a percutaneous 
approach, and therefore a minimum of two to three needle 
passes is usually required to obtain an adequate sample.
TJLBs are performed with dedicated kits that include long 
sheaths and 18 G or 19 G automated cutting- type biopsy needles 
of appropriate length (such as the Quick- Core biopsy needle, 
Cook Medical, Bloomington, Illinois, USA). An alternative 
needle sometimes used is the modified Ross aspiration biopsy 
needle. Multiple retrospective studies over the past few decades 
have all demonstrated the safety and diagnostic adequacy of 
TJLB with an automated cutting biopsy needle or modified 
Ross biopsy needle.89 91 Fragmentation of samples is a problem 
with both types of transjugular needles, however, less so with 
the cutting type, as demonstrated in randomised trials and case–
control studies.92–94 Comparative studies demonstrate that while 
the diagnostic adequacy of the samples is higher through PLB, 
samples obtained by TJLB are sufficient to make a diagnosis and 
equally safe.95–97 Thus, in the presence of contraindications to 
PLB, TJLB provides an equally safe and adequate technique to 
obtain liver tissue, with cutting- type needles being preferred 
over aspiration- type needles.
TJLB is associated with minor and major complication rates of 
6.5% and 0.56%, respectively, but unlike percutaneous biopsy, 
is uncorrelated with the number of passes. Mortality can occur 
from major haemorrhage (0.06%) or ventricular arrhythmia 
(0.03%). TJLB can be done relatively safely even if the clotting 
is significantly deranged.98 99
Transfemoral liver biopsy
A transfemoral approach may occasionally be used when a tran-
sjugular approach has failed or is not technically feasible, as in 
patients with internal jugular vein thrombosis. The procedure 
may be performed via an inferior accessory hepatic vein or by 
direct puncture through the hepatic portion of the inferior vena 
cava.100 Alternative techniques, to obtain specimens from one of 
the main hepatic veins using endoscopic forceps, has also been 
described.101
Endoscopic ultrasound (Eus) guided liver biopsy
With increasing experience in the use of EUS in the liver, several 
series have reported its use in performing both non- targeted and 
targeted liver biopsies, with diagnostic yield of 90–100% and a 
low complication rate, even when using 19 G needles.102–104 One 
recent retrospective, non- randomised, single- centre study105 of 
90 patients found that the biopsy specimens obtained by the 
percutaneous route, compared with the EUS route, gave signifi-
cantly more portal tracts (13 vs 5) and were more likely to enable 
a histological diagnosis (100% vs 93%), although those patients 
in the ultrasound group had a significantly shorter hospital stay 
(median hospital stay 3 vs 4.2 hours) and reported less pain 
(median pain score 0 vs 3.5). A tip- core biopsy needle delivers 
bigger samples than fine- needle aspiration biopsy needles.106
Laparoscopic liver biopsy
The laparoscopic technique is long established and is used in 
patients with coagulopathy where TJLB is unavailable or has 
failed. It is also used when biopsy of a focal liver lesion is required 
in the setting of severe coagulopathy. It enables direct visualisa-
tion of the liver and coagulation of the biopsy site to control 
any bleeding. Previous cross- sectional imaging can inform the 
surgeon of any anatomical contraindications to laparoscopic 
biopsy, such as a large abdominal aortic aneurysm or adherent 
small bowel loops. A laparoscopic biopsy is performed in an 
operating theatre with appropriate infection control techniques.
Laparoscopic liver biopsy may be done via a conventional 
laparoscopy or mini- laparoscopy, with the latter performed 
under local anaesthesia and conscious sedation.107 108 Laparo-
scopic liver biopsy generally entails performing liver biopsy 
through the laparoscope port using a long cutting- type needle. 
There is limited literature on this technique; however, a retro-
spective comparative study comparing laparoscopic liver biopsy 
using cutting- type needles with a percutaneous blind liver biopsy 
with a Menghini needle demonstrated its superiority in diag-
nosing background diffuse liver disease in patients with hepato-
cellular carcinoma.109 A further randomised controlled trial of 
laparoscopic liver biopsy versus PLB showed that the former, 
combining both macroscopic and histological assessment, was 
more sensitive for the diagnosis of cirrhosis and had a similar 
safety profile.110
The complications of laparoscopic liver biopsy include those 
of the laparoscopy itself.
Open wedge liver biopsy is also very occasionally performed, 
mostly in the setting of bariatric surgery, although its usefulness 
10 Neuberger J, et al. Gut 2020;0:1–22. doi:10.1136/gutjnl-2020-321299
Guidelines
remains unclear but may help to identify fatty liver disease (see 
online supplementary appendix).111 112
Recommendations
 ► We recommend that there should be agreed formal path-
ways for access, in a timely fashion, to a regional or tertiary 
centre that can offer these facilities when clinically indicated 
(strength of recommendation STRONG; evidence WEAK).
morbidiTy And morTALiTy
The indications, methods and practice of liver biopsy have 
evolved, so extrapolation of complications of the procedure to 
current practice must be done with caution. All invasive proce-
dures have an associated risk of both morbidity and mortality, 
and thus the risks of biopsy need to be balanced against the 
benefits of having histology or other data to help manage the 
patient's condition. It must be emphasised that the development 
of complications does not necessarily imply error by the health-
care professional.
pErCuTAnEous biopsy
Reported morbidity and mortality associated with percuta-
neous liver biopsy varies considerably. Reasons for this variation 
include the fact that many of the larger studies are retrospec-
tive,113 114 indications and practice have changed over time, there 
is little consistency in the definitions of the complications and 
many studies do not distinguish between death as a direct conse-
quence of the biopsy and death from other causes.
Mortality at 3 months after liver biopsy has been reported 
to be as high as 19%,32 but many of these deaths are related to 
the underlying condition rather than the biopsy itself. In this 
audit of 1500 liver biopsies, 26 (1.7%) were associated with 
bleeding: blood transfusion was required in 11 (0.7%), one 
required laparotomy. The proportion of bleeding episodes was 
higher in those with prolonged clotting (3.3% in those with 
INR 1.3–1.5% and 7.1% in those with INR >1.5); bleeding was 
also more common in those with raised serum bilirubin (2.7% 
compared with 1.1%) and low platelet count (<150×109/L; 
2.9%, compared with 1.6% in those with higher platelet 
counts). No difference in bleeding was found between guided 
and blind biopsies. With respect to mortality, two deaths were 
directly attributed to the biopsy and three additional deaths 
were possibly attributable to the biopsy; the authors concluded 
that the death rate attributable to the liver biopsy was between 
0.13% and 0.33%.
One of the largest studies was reported by Piccinino and 
colleagues in 1986,50 where outcomes of 68 276 liver biopsies 
in 36 liver units in Europe were retrospectively analysed. Of the 
bleeding complications, haemoperitoneum was reported in 22 
(0.032%), intrahepatic haematoma and haemobilia in 0.006% 
each and haemothorax in 0.022%. Infection occurred in 0.01%—
all in association with a Menghini technique; perforation of 
other organs was reported as pneumothorax in 24 (0.35%), lung 
puncture in 1 (0.014%), colon puncture in 2 (0.003%), kidney 
in 2 (0.003%) and gall bladder in 8 (0.012%), again all with 
Menghini technique. Six deaths (0.009%) occurred, all in those 
with cirrhosis or neoplastic disease.
In a retrospective study in England, West and Card115 analysed 
the mortality associated with elective percutaneous liver biopsy 
in 61 187 patients between 1998 and 2005. Overall all- cause 
mortality by 7 days after biopsy was 2 per 1000 biopsies (95% CI 
1.8 to 2.5), with rates as high as 12 per 1000 for patients inves-
tigated for cancer. Death within 7 days directly related to liver 
biopsy occurred, at most, every 1 in 10 000 biopsies in patients 
investigated for liver disease or abnormal liver function test 
results. Major bleeding occurred in about 6 per 1000 biopsies.
A retrospective study from Australia35 examined records from 
1398 patients over a 20- year period. Major complications were 
found in 12 (1.0%): haemorrhage (10), bile leak and visceral 
perforation (1 each). Seven of these patients had an abnormal 
baseline coagulation profile; a significant risk for major haemor-
rhage (p<0.001), resulting in three deaths. All deaths occurred 
in inpatients with major comorbidities. Minor complications 
occurred in 13.6% of patients: multiple passes were a significant 
risk factor. The effect of time was apparent: the rates of both 
bleeding and death were greater in the period 1986–1995 than 
1996–2005 (bleeding with normal coagulation profile 0.5% vs 
0.13%; mortality 0.45% and 0.13%, respectively).
A much larger retrospective study of 15 181 percutaneous 
liver biopsies at the Mayo Clinic116 reported 70 cases of haem-
orrhage (0.5%) that were Common Terminology Criteria for 
Adverse Events (CTCAE) grade 3 or greater, identified within 3 
months of biopsy. The incidence of bleeding in patients taking 
aspirin within 10 days before biopsy was 0.6%, which was not 
statistically different from the incidence of bleeding in those 
not taking aspirin (0.4%). Significant associations were found 
between major bleeding and serum platelet count and INR 
(p<0.001), although the association between major bleeding 
and the size of the biopsy needle was not significant (p=0.97). 
A later study117 from the same institution examined complica-
tions in a large series of adult patients using image- guided liver 
biopsies. Of 6613 biopsies performed in 5987 adult patients, 
there were 49 acute and delayed major adverse events (0.7%). 
The incidence of haematoma requiring transfusion and/or angio-
graphic intervention was 0.5% (34); of infection 0.1% (8), and 
haemothorax 0.06% (4). No patient had a pneumothorax. 
Three patients (0.05%) died within 30 days of liver biopsy, one 
being directly related to biopsy. Most of the major adverse events 
(83%) presented acutely within 24 hours. More than two biopsy 
passes, platelets ≤50 000/μL and female sex were statistically 
significant risk factors for post- biopsy haemorrhage.
In a study of 4275 liver biopsies in 2002, Myers et al118 
reported a bleeding rate of 0.35% and a mortality of 0.14% (six 
patients, five of whom died from bleeding and one from aspira-
tion pneumonia).
Firpi and colleagues,119 in a survey of 3214 biopsies, 
reported a death rate of 0.06% (one each from blood loss and 
haemothorax). They noted that the introduction of ultrasound- 
guided biopsy was associated with a fall in haemothorax from 8 
(0.2%) to nil.
Howlett et al8 undertook a retrospective audit of liver biop-
sies in the UK in radiology departments and centres were asked 
to provide data on 50 consecutive liver biopsies. Eighty- seven 
(41%) of 210 departments responded. Information was provided 
on 3496 cases (1225 for focal disease). Ultrasound guidance was 
the most commonly used technique. Four haemorrhage- related 
deaths occurred (0.11%, all in patients with targeted biopsies for 
malignancy). Fifteen additional patients experienced at least one 
major complication: haemorrhage in 14, haemobilia in 2: extra-
hepatic organs punctured included kidney, lung, gall bladder and 
bowel (one case each). Post- biopsy procedures included transfu-
sion (12), percutaneous draining (4), laparotomy (1) and embo-
lisation (2).
Gupta and colleagues,120 on behalf of the Society of Inter-
ventional Radiology, reported complication rates of between 
0.3% and 3.3% and divided complications in to minor (no 
therapy or nominal therapy (which included overnight stay for 
observation only)) and major complications (which included 
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requiring therapy with hospital stay <48 hours, major therapy 
which required increased level of stay for >48 hours, long- term 
sequelae and death).
A recent meta- analysis of bleeding after percutaneous liver 
biopsy121 concluded that ‘bleeding of any kind occurred in up 
to 10.9% of image- guided liver biopsies, with major bleeding 
episodes ranging from 0.1% to 4.6% and minor bleeding 
events occurring in up to 10.9% of biopsies. The overall rate of 
bleeding was <2%. Risk factors for increased risk of bleeding 
included patient age (>50 years or <2 years), comorbidities 
and/or concurrent diagnoses and coagulation status. The rate 
of bleeding was 3.3% if the INR was 1.2–1.5% and 7.1% if 
the INR was >1.5. Operator experience (>200 biopsies/year 
vs <50/year) did not affect the post- biopsy bleeding rate. 
Procedure- related risk factors included needle size (cutting 
biopsy compared with fine needle aspiration) and the pres-
ence of a patent track on post- biopsy ultrasound. There was no 
difference in bleeding rates between targeted and non- targeted 
biopsies and number of needle passes. One of most recent meta- 
analyses of ultrasound- guided liver biopsy included 12 481 
patients enrolled in 51 studies. The subgroup analysis indicated 
that ultrasound- guided liver biopsy had a low major complica-
tion rate for core biopsies, with rates of 0.016 for 14 G, 0.010 
for 15 G, and 0.002 for 20 G, and low minor complication 
rates of 0.001 for core biopsy. Remarkably, specific complica-
tion rates of bleeding, pain, pneumothorax, vasovagal reactions 
and death were all nil.122
Other studies in adults or children have reported major bleeding 
episodes occurring in up to 2.5% and minor bleeding in up to 
15%36 45 46 123–126 in patients undergoing blind or ultrasound- 
guided biopsies. Nonetheless, a small fall in haemoglobin is often 
seen, in the absence of overt signs of haemorrhage.127
Transjugular liver biopsy (TJLb)
Indications for TJLB are usually different from those of percu-
taneous biopsy so direct comparison of morbidity and mortality 
between the two approaches may lead to misleading conclu-
sions. Kalambokis98 reviewed complications from TJLB in 64 
series reporting 7649 TJLBs evaluating the quality of specimen 
and safety. Minor and major complication rates were 6.5% and 
0.56%, respectively, and increased in children, but not with 
additional passes. In adults, mortality was 0.09% (haemorrhage 
0.06%; ventricular arrhythmia 0.03%).
In a Canadian retrospective review of 461 biopsies performed 
over a 7- year period, Gamble128 reported minor complications 
such as neck pain, haematoma at the puncture site, or fever 
occurring in 79 patients (17.1%). Two patients died, but the 
biopsy was considered a factor in one (overall mortality 0.5%). 
Bleeding occurred from the puncture site in the neck in 8 (1.7%), 
carotid artery puncture in 3 (0.7%) and intraperitoneal haemor-
rhage in 4 (0.9%). Capsular perforation occurred in 18 (3.9%) 
and resolved with Gelfoam in 17. Modification of the technique 
by taking the biopsy with the catheter positioned centrally rather 
than wedged peripherally reduced the occurrence of capsular 
perforation without affecting the success rate.
An analysis by McAfee129 found the reported mortality of TJLB 
was 0 in three major centres and ranged from 0.1% to 0.5% in 
three other centres. Velt,130 in a series of 160 patients, recorded 
only one case of pneumothorax and no deaths. Kis,131 examining 
complications of 166 TJLBs in 141 haematopoietic stem cell 
transplants at one institution, reported three major complica-
tions (1.8%), including one death. Complications may be greater 
in those biopsied after bone marrow transplantation.132
Endoscopic ultrasound-guided biopsy
Endoscopic ultrasound- guided liver biopsy (EUS- LB) may be a 
safe and effective alternative approach to percutaneous or tran-
sjugular biopsy in the evaluation of both benign and malignant 
diseases of the liver. It can offer higher resolution imaging of 
the liver and can detect smaller lesions than CT or US scans of 
the abdomen. Evidence suggests the superiority of EUS- LB for 
a targeted approach of focal lesions, with less sampling vari-
ability in heterogeneous parenchymal disease.133 Mohan and 
colleagues134 recently published an analysis of a systematic 
review and meta- analysis of reports of complications of EUS- 
guided liver biopsy. Of the nine study arms with 437 patients, 
the pooled rate of adverse events with EUS- LB was 2.3% (95% 
CI 1.1% to 4.8%, I2=0). On subgroup analysis, the adverse 
events rate with a 19 G fine needle aspiration (FNA) needle (vs 
other core biopsy needles) was 0.9% (vs 2.7%, p=0.28).
Laparoscopic liver biopsy
A retrospective study of 2731 consecutive patients undergoing 
diagnostic mini- laparoscopy at two university hospitals in 
Germany135 found that major complications occurred in 1.0% 
(n=27): these included delayed bleeding from the liver biopsy 
site or abdominal wall (0.7% of patients) and intestinal perfora-
tion (0.3% of patients). Two patients died after severe haemor-
rhage (mortality 0.07%); the other patients recovered without 
sequelae. The risk of bleeding was increased in patients with 
low platelets (OR=6.1), increased INR (OR=8.9), cirrhosis 
(OR=1.9) and portal hypertension (OR=2.1). Logistic regres-
sion showed a significant correlation only for the concurrence 
of low platelets and increased INR; bootstrap analysis identified 
INR >1.5 as a significant predictor. Prior abdominal surgery 
did not carry a significant risk for intestinal perforation unless 
abdominal adhesions were present.
Conclusions
The reported risk of death and complications vary. Some of the 
variation can be attributed to the inherent limitations in large 
retrospective studies, the lack of agreed definitions of compli-
cations, the clinical condition of the patient, the type of biopsy 
procedure and changes in practice over time.
Recommendation
When obtaining consent from patients, clinicians must use 
local data where available, tailored to the patient’s individual 
situation (strength of recommendation STRONG; evidence 
HIGH).
hAEmAToLoGiCAL ConsidErATions
Since the publication of the previous version of these guidelines, 
there have been major advances in the understanding of coag-
ulation in health and liver disease, in the methodologies avail-
able to assess different aspects of coagulation and treatments for 
anticoagulation. Guidelines have been developed by the British 
Society of Haematology136 137 and the American Gastroenter-
ology Association.138
Coagulation testing
Understanding of the coagulation profile in liver disease has 
evolved since the previous guideline was written. Historically, it 
was assumed that the raised prothrombin time often seen in liver 
disease, commonly expressed as an INR, reflected a bleeding 
risk and that correction with plasma products, specifically fresh 
frozen plasma (FFP), would reduce/correct this haemostatic 
failure. However, more recent studies have shown quite the 
12 Neuberger J, et al. Gut 2020;0:1–22. doi:10.1136/gutjnl-2020-321299
Guidelines
reverse; that there is often a prothrombotic state, and transfu-
sion of FFP has been described as usually unnecessary, ineffec-
tive and potentially hazardous.139–145 A recent Cochrane review 
concluded that there is uncertainty about the utility and safety 
of prophylactic FFP use.146 Thus, use of FFP is rarely indicated.
Although there is reduced synthesis/consumption of many 
procoagulant proteins and reduced numbers of platelets, there is 
an increase in factor VIII and von Willebrand Factor and a reduc-
tion in natural anticoagulants. Haemostasis in chronic stable 
liver disease is often referred to as ‘rebalanced’ with a net effect 
of normal haemostasis or even a procoagulant state and this is 
reflected in more ‘global’ assays of coagulation in patients with 
chronic liver disease, such as thrombin generation and visco-
elastic haemostatic assays.147–154 There appears to be a similar 
rebalancing in acute liver disease.155
The INR is only sensitive for fibrinogen, factor II, factor V, 
factor VII and factor X and does not test the haemostatic balance 
in a patient with liver disease. The INR has been shown to be a 
poor predictor of bleeding during liver transplantation, and this 
procedure is now often done without the need for blood product 
replacement.145 156
There is also a paucity of data to recommend a ‘safe’ minimum 
platelet number for procedures in patients with chronic liver 
disease, and whether platelet transfusion is effective.150 157 158 
Common practice has been to consider transjugular over percu-
taneous biopsy in patients with a platelet count <50×109/L and/
or to transfuse platelets. There is no clear evidence regarding the 
efficacy and safety of platelet transfusions under these circum-
stances and increments may be poor and short lived in patients 
with portal hypertension.
More recent studies of thrombopoietin receptor agonists 
(TPO- RAs) have been shown to reduce the need for platelet 
transfusion in patients with cirrhosis requiring elective invasive 
procedures.103 138 159 160 It is plausible that TPO- RAs provides a 
more effective haemostatic effect than platelet transfusion. The 
treatment period required prior to biopsy is 9–14 days. Although 
not seen in all studies, TPO- RAs have been associated with 
an increased risk of thrombosis, including portal vein throm-
bosis,161 so should be used with caution in patients considered to 
be at higher risk of thrombosis, especially as these patients were 
excluded from trials. In the UK, NICE has recently concluded 
that lusutrombopag is recommended, within its marketing 
authorisation, as an option for treating severe thrombocytopenia 
(that is, a platelet count of <50×109/L) in adults with chronic 
liver disease having planned invasive procedures; no recommen-
dations were made about avatrombopag until it has an agreed list 
price in the UK.162
In a large retrospective study of patients having percutaneous 
liver biopsy,163 implementation of less stringent preprocedural 
coagulation parameters (INR ≤2.0, platelets ≥25 x109/L) was 
associated with fewer haemorrhagic complication rates and a 
significant decrease in preprocedural FFP/platelet administra-
tion in comparison with using historical cut- off points (INR 
≤1.5, platelets ≥50 x 109/L). Of note, haemorrhagic complica-
tion rates did increase as the INR increased and platelet counts 
decreased, but preprocedural FFP and/or platelet transfusion 
did not have a significant effect on haemorrhagic complication 
rates. While the results of conventional clotting tests correlate 
poorly with duration of bleeding and blood loss following liver 
biopsy,164 165 some retrospective studies do show an increased 
bleeding with an elevated INR,32 135 although the INR is gener-
ally not an independent risk factor for bleeding.166 A plausible 
explanation is that changes in the INR and platelet count are 
a surrogate marker for liver fibrosis and portal hypertension, 
which in itself will be a risk factor for bleeding; however, 
attempts to correct these haemostatic changes may increase 
bleeding risk as haemostatic failure is not the underlying cause 
of bleeding and increasing the intravascular volume is likely to 
be counterproductive.
The recent guidelines from the American Gastroenterology 
Association138 include the recommendations that blood products 
should be used sparingly because they increase portal pressure 
and carry a risk of transfusion- associated circulatory overload, 
transfusion- related acute lung injury, infection transmission, 
alloimmunisation and/or transfusion reactions.
The following transfusion thresholds for management of active 
bleeding or high- risk procedures may optimise clot formation in 
advanced liver disease: haematocrit ≥25%, platelet count >50 x 
109/L, and fibrinogen >120 mg/dL. Commonly used thresholds 
for correction of the INR are not supported by evidence.
The large volume of fresh frozen plasma required to reach 
an arbitrary INR target, limitations of the usual target, minimal 
effect on thrombin generation, and adverse effects on portal 
pressure limit the usefulness of this agent considerably.
In contrast, decompensated liver disease with acute or chronic 
liver failure is associated with a progressive consumptive coagu-
lopathy and hypofibrinogenaemia, often with hyperfibrinolysis. 
Spontaneous mucocutaneous and other bleeding manifestations 
may become evident at this stage. In one study, a platelet count 
<30×109/L, fibrinogen level <0.6 g/L and activated partial 
thromboplastin time values >100 s were the strongest inde-
pendent predictors for new onset of major bleeding.167 All but 
the most essential invasive procedures should be avoided under 
these circumstances. Acute kidney injury has also been associated 
with an increased risk of bleeding after paracentesis in patients 
with decompensated cirrhosis.168
Treatment with vitamin K should be considered in patients 
with an increased INR, which may in part reflect vitamin K defi-
ciency; particularly in patients in intensive care, in patients with 
malnutrition, in patients using antibiotics and in patients with 
cholestatic liver disease.147 169
Increasing evidence shows that viscoelastic assays can be used 
to assess haemostatic status in patients with liver disease, with 
evidence that this can result in a reduction in blood products 
transfused.170–174 This has become increasingly established 
in liver surgery but more recently for other procedures. In a 
small randomised trial, De Pietri175 showed that in patients with 
cirrhosis and an INR >1.8 and/or platelet count <50×109/L 
requiring invasive procedures, a thromboelastogram- guided 
transfusion strategy led to a significantly lower use of blood 
products (17% compared with 100% transfusion in the stan-
dard of care group) without an increase in bleeding compli-
cations; only one major bleed occurred, which was in the 
standard of care group. This has been shown in other open- 
label randomised studies.176 Viscoelastic testing has therefore 
been used successfully to reduce unnecessary prophylactic 
transfusions in patients with liver disease (in comparison with 
using the INR and platelet count). In contrast, in a single- centre 
randomised study of central venous catheter insertion in patients 
with cirrhosis, a thromboelastography- based strategy did not 
reduce blood transfusion compared with usual care; however, a 
restrictive protocol (no transfusion unless INR >5.0 or platelet 
count <25×109/L) reduced transfusion without an increase in 
bleeding.177 It should also be noted that these assays have not 
yet been shown to reliably predict bleeding in patients with liver 
disease.150 178
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Antiplatelet agents
The British Society for Haematology has produced guidelines on 
perioperative management of anticoagulation and antiplatelet 
therapy, although there are no specific recommendations for 
patients requiring liver biopsy.137 There is increasing use of 
P2Y12 inhibitors in patients with vascular disease and after arte-
rial stenting (such as clopidogrel/prasugrel/ticagrelor). The anti-
platelet effect persists for up to 7–10 days. It is common practice 
to pause these drugs approximately 7 days prior to elective proce-
dures associated with a bleeding risk. Data in relation to trans-
cutaneous liver biopsy are insufficient to recommend otherwise, 
and the haemostatic effects of P2Y12 inhibitors may be difficult 
to reverse (table 2). In a study of 8172 percutaneous ultrasound- 
guided intra- abdominal interventions, the frequency of bleeding 
was reported as significantly higher in patients taking medication 
interfering with platelet function or coagulation.34 In one retro-
spective study of CT- guided liver biopsies, aspirin use within 10 
days had no significant impact on bleeding116; however, there 
was insufficient detail to determine whether closer proximity to 
biopsy time was a risk factor. The haemostatic effects of aspirin 
are more readily reversed, and indirect evidence suggests that 
treatment with aspirin can be paused for a shorter period (such 
as 3 days) prior to invasive procedures.179 180 Empirical experi-
ence (such as with post liver transplant biopsies) suggests that 
pausing aspirin may not be necessary and should be at the discre-
tion of the operator if urgent. As with all clinical decisions, the 
risks of stopping anti- platelet drugs must be carefully considered 
and, where appropriate, consultant advice sought, especially in 
patients with recent stents/percutaneous coronary intervention if 
the procedure cannot be delayed.
Anticoagulants
Warfarin should be stopped 5 days before the procedure with 
point- of- care testing before the procedure to ensure adequate 
reversal (table 2). Bridging treatment with low molecular weight 
heparin should be started if deemed necessary.137
Direct oral anticoagulant drugs should be stopped for 2 days 
prior to the day of the biopsy or longer if taking dabigatran, 
depending on the renal function.181
Recommendations
For a non- lesional liver biopsy, we recommend a transve-
nous approach if the INR is >1.4 (strength of recommendation 
MODERATE; evidence MODERATE).
If a percutaneous targeted biopsy is required in a patient with 
stable liver disease, an INR of 1.5–2.0 is not a contraindication; 
however, the risk of bleeding may be higher in the context of 
liver fibrosis and portal hypertension (strength of recommenda-
tion MODERATE; evidence MODERATE).
We recommend FFP should not be used to correct an INR ≤2.0 
prior to liver biopsy (strength of recommendation STRONG; 
evidence MODERATE).
We recommend that, where time allows, stopping aspirin 3 
days prior to percutaneous biopsy should be considered, but 
the decision will depend on the indications for aspirin and the 
urgency of the biopsy (strength of recommendation MODERATE; 
evidence WEAK).
In patients with acute kidney injury or acute or chronic/
decompensated liver disease, we recommend that liver biopsy 
should be avoided whenever possible as these conditions are 
often characterised by a consumptive coagulopathy and low 
fibrinogen, so these patients are at high risk of bleeding. Labo-
ratory parameters associated with a particularly high risk of 
bleeding include a platelet count <30×109/L, fibrinogen level 
<0.6 g/L and activated partial thromboplastin times >100 s. If 
liver biopsy is necessary for clinical management, a transjugular 
route should be used (strength of recommendation STRONG; 
evidence MODERATE).
We recommend that vitamin K depletion should be corrected 
before liver biopsy (strength of recommendation STRONG; 
evidence WEAK).
We recommend that patients with a history of abnormal 
procedure- related bleeding, unrelated to portal hypertension, 
should be referred for specialist haematology assessment prior to 
biopsy (strength of recommendation STRONG; evidence WEAK).
The routine use of global haemostatic tests is not recom-
mended at this time (strength of recommendation LOW; 
evidence WEAK).
Where the platelet count is <50 x 109/L, a transvenous 
approach is recommended, where possible (strength of recom-
mendation STRONG; evidence MODERATE).
The effectiveness and risks of platelet transfusion for a 
platelet count <50×109/L have not been established but can be 
considered (strength of recommendation MODERATE; evidence 
WEAK).
TPO- RAs are an alternative to platelet transfusion according 
to local protocol (strength of recommendation MODERATE; 
evidence HIGH).
Recommendations: when to stop anticoagulants and anti-
platelet drugs—see table 2 (strength of recommendation 
STRONG; evidence WEAK).
GEnErAL prinCipLEs for informEd ConsEnT
Informed consent should be obtained from all patients prior to 
percutaneous liver biopsy in accordance with national and local 
hospital guidelines182 For consent to be valid, it must be volun-
tary and informed, and the person consenting must have the 
ability to make the decision.
Where possible, the patient should be given information in 
advance of the procedure. Ideally, information should be given 
verbally and supplemented by written or other media. Consent 
should be confirmed in writing prior to the biopsy procedure 
in accordance with individual hospital policies. Consent forms 
should be written in the patient’s native language wherever 
possible and when this is not possible, there should be access 
to a competent interpreter to ensure adequate understanding by 
the patient of both the risks and benefits of the procedure and 
commands given to them during the biopsy.
Information should be given about the risks of the proce-
dure and the benefits and alternative approaches (if any). When 
figures are presented to patients, it is better to avoid giving 
percentages or rates; instead, we recommend that information 
should be presented as ‘of 1000 people like you undergoing liver 
biopsy, 4 will require a blood transfusion’).183
If an adult has the capacity to make a voluntary and informed 
decision to consent to, or refuse, the procedure, their decision 
must be respected.
Some patients may lack capacity to give informed consent. If a 
person is unable to make a decision, understand the information 
relevant to the decision, retain the information or communicate 
his or her decision (by any means), then special consent must 
be obtained. Capacity must be assessed prior to consent. If a 
person does not have the capacity to make a decision about their 
treatment and has not appointed a lasting power of attorney, 
the healthcare professionals treating them may go ahead with 
the procedure if they believe it is in the person's best interests 
in accordance with the relevant national and local guidance. 
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box 2 issues when considering liver biopsy
When requesting and when performing liver biopsy
What is the indication for the biopsy?
Current medication and allergies
Current and past medical history
Can the patient understand and follow simple instructions?
Can the patient comply with aftercare instructions—for 
example, lying flat?
Have plans for after- care been established?
Is there increased risk for staff?
Review of recent blood tests:
full blood count, including platelets
clotting studies
renal and liver function
Review of imaging:
Shape and size of liver
Any abnormal anatomy?
Any evidence of ascites?
Other structural elements (such as atypically located 
bowel or gall bladder, cysts, etc)
Handling of histological specimen? (for example, for 
metabolic or microbiological studies)
When requesting liver biopsy
Is antimicrobial prophylaxis indicated
What approach is optimal
Is clotting/platelet support indicated and, if support required, 
is this adequate?
Should drug regimen be modified
immediately prior to biopsy
Is this the right patient? Usually three points of identification 
are required
Has the patient given fully informed consent and is the 
consent current?
Are all relevant personnel present and does everyone 
understand their role?
Have antimicrobials or clotting factors been given, where 
appropriate, and, if so, when?
Has routine medication been modified (if appropriate)?
Is there established venous access?
Is all the necessary equipment present and working 
effectively?
Is there appropriate emergency support?
The basis for the decision should be clearly documented in the 
patient’s records.
Liver biopsy solely for research purposes
Material obtained from a liver biopsy taken specifically for 
research has provided invaluable information for understanding 
the pathogenesis and treatment of disease. However, when the 
patient will derive no direct therapeutic benefit from the proce-
dure and will only accrue the risks of that procedure, the patient 
should be fully aware of this and give written consent.
If part of the liver biopsy done for diagnostic or therapeutic 
purposes is taken for research, or if additional passes will be 
done to obtain material for research purposes, the patient must 
be given this information and give full consent. The procedure 
will also need approval from the appropriate research ethics 
committee (or equivalent) and hospital board.
Recommendations
 ► Patients should be given information about the risks and 
benefits of the procedure, in advance of the procedure where 
possible (strength of recommendation STRONG; quality of 
evidence HIGH).
 ► Information should be given verbally and supplemented by 
information in written form or other media using language 
understood by the patient (strength of recommendation 
STRONG; quality of evidence HIGH).
 ► Information on risks should be readily understood and the 
following is recommended ‘of 1000 people like you having 
a liver biopsy, X will develop (complication)’ (strength of 
recommendation MODERATE; evidence WEAK)
 ► Consent should be confirmed in writing and local and 
national guidelines followed (strength of recommendation 
STRONG; evidence HIGH).
 ► Where a liver biopsy is done solely or partly for research, 
patients must be fully informed, and the procedure must be 
approved by the appropriate research ethics committee (or 
equivalent) and hospital regulations (strength of recommen-
dation STRONG; evidence HIGH).
CLiniCAL ConsidErATions
In assessing the patient for a liver biopsy, the clinician requesting 
the biopsy and the operator performing the liver biopsy need to 
ensure that, unless there is mental incapacity, the patient under-
stands the purpose of the liver biopsy and has given properly 
informed consent, and the benefits of the findings of the biopsy 
justify the risks.
To ensure that the biopsy can be done as safely and effectively 
as possible, the healthcare professionals need to consider the 
factors indicated in box 2
role of antimicrobial prophylaxis
See section 'Prophylactic antibiotics'. Routine antimicrobial 
prophylaxis is not indicated except in the presence of biliary 
sepsis or a Roux loop in a liver allograft.
percutaneous biopsy
Practice varies as to whether patients should be advised to be nil 
by mouth before a biopsy; some centres advise a minimum of 
2 hours’ fast but there is little evidence on which to make a firm 
recommendation.6
For the procedure itself, the patient is normally supine, in a 
comfortable position, with the right hand resting comfortably 
behind the head or by their side. Where the patient is anxious, 
sedative medication may be used, according to local guidelines.
Once the site of biopsy is identified, the skin should be cleaned 
and then the patient is given a local anaesthetic, typically with 
1% lidocaine. Where appropriate, the anaesthetic should be 
infiltrated into the capsule. As the liver moves during respi-
ration, breathing while the biopsy needle is in the liver may 
cause laceration and bleeding. As a consequence, patients are 
usually asked to hold their breath while the needle is in the liver. 
Although there is some variation in practice, most centres advo-
cate the operator taking the biopsy when the patient has taken 
a deep expiration as this will reduce the risk of pneumothorax. 
Whichever cycle of respiration is chosen, it is important that the 
biopsy itself is done during the same part of the cycle as used to 
identify the optimal site of biopsy.
Recommendation
 ► Percutaneous liver biopsy for non- lesional indications 
should be done with the patient holding their breath in 
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expiration (strength of recommendation MODERATE; 
quality of evidence LOW).
After the procedure
After the procedure the patient is instructed to remain in the 
recumbent position for the duration of the post- procedure 
monitoring. Some centres advocate that the patient should lie 
on their right side, in the belief that that the pressure of the 
liver will reduce the risk of bleeding. In one small study,184 this 
was associated with more pain but no difference in complica-
tions. The duration of monitoring will be up to 8 hours, but 
for the low- risk patient with no post- biopsy complications, 
3 hours' observation is usually adequate,119 although one recent 
study suggested that 1 hour is enough to recognise all major 
complications.185
Liver biopsy observations include monitoring the patient’s 
pulse rate and blood pressure every 15 min for the first hour,119 
then every 30 min for 2 hours and then hourly for the remaining 
period. If the patient is hypotensive or tachycardic then they 
should receive 500 mL of 0.9% saline, unless contraindicated, 
and then re- evaluated.
The biopsy site should be checked every half hour for signs 
of bleeding.
Patients should be discharged only if they are haemodynami-
cally stable with no evidence of bleeding, stable blood pressure 
and no new complaints of pain or shortness of breath.186
1. Before discharge, patients should be given oral and written 
instructions regarding further monitoring and daily activi-
ties. The information should also include details of who to 
contact and how to contact them, in the event of complica-
tions or other concerns. Instructions should include advice 
to rest for the remainder of the day and not drive any motor 
vehicles or operate any heavy machinery on the day of the 
biopsy. Strenuous physical activities such as running, contact 
sports or heavy lifting for 48 hours after the biopsy are dis-
couraged, although the evidence for this recommendation is 
weak.
2. If a patient experiences any symptoms such as chills, high 
fever, difficulty breathing, excessive bright red bleeding from 
the biopsy site, severe chest, shoulder or abdominal pain, 
passing blood in the stool or increasing abdominal swelling, 
then they are instructed to call the hospital.
Recommendation
 ► Patients should be monitored for at least 3 hours after liver 
biopsy with regular clinical observations and measurement 
of blood pressure and pulse (strength of recommendation 
STRONG; evidence WEAK).
outpatient day case liver biopsy
It is recommended that patients undergoing day case percuta-
neous liver biopsy should have no conditions that might increase 
the risk of biopsy; these include encephalopathy, ascites, malig-
nancy, hepatic failure with severe jaundice or evidence of signif-
icant extrahepatic biliary obstruction, significant coagulopathies 
or serious diseases involving other organs, such as severe conges-
tive heart failure or advanced age.187 Pragmatic issues that will 
affect the decision not to undertake day case biopsy includes the 
travel time between the hospital and patient’s home (or place of 
recovery), domestic situation and time of day that the biopsy is 
done.
Patients with a strong suspicion of malignancy should not be 
biopsied as a day case because such patients may have a higher 
risk of haemorrhage than patients without cancer.65
Day case biopsy should be done only where there is speedy 
access to a diagnostic laboratory, blood bank and in- patient facil-
ities and when there are staff to observe the patient after the 
biopsy.
Recommendation
 ► Liver biopsy may be safely done as a day case procedure if 
there are no increased risk factors and the patient can be 
looked after when they have left hospital, can seek appro-
priate advice and access appropriate medical help if needed 
(strength of recommendation STRONG; evidence WEAK).
pAThoLoGiCAL ConsidErATions
Liver histology continues to provide information for diagnosis 
and prognosis of the patient where this cannot be obtained by 
non- invasive means (see box 1). This can be achieved only if 
the biopsy is of sufficient length and quality and examined by a 
suitably experienced histopathologist.
The scope and use of non- invasive tests is increasing, radi-
cally altering the need for liver biopsy. In particular, the number 
of biopsies obtained to assess disease severity when the diag-
nosis is established is falling. However, liver histology remains 
useful when clinical parameters and non- invasive tests suggest 
that there is more than one potential aetiological agent or give 
conflicting information.
size of biopsy
For medical liver biopsies, the core of tissue should be intact and 
of sufficient size to demonstrate the lobular architecture of the 
liver over several portal tracts. Portal tracts and hepatic veins 
are about 0.8 mm apart and therefore better seen on a biopsy 
of around 0.8–1 mm in diameter, such as is obtained using a 16 
G needle. The size and integrity of the sample is particularly 
important when being taken to investigate the stage of fibrosis 
in chronic liver disease,188 or in diseases which affect the liver in 
a variable way—for example biliary disease.189 There is agree-
ment that the minimum biopsy sample for clinical trials purposes 
should be 20 mm obtained with a 16 G needle.71
Good evidence shows that a biopsy containing 10 or fewer 
portal tracts results in underestimation of both the severity of 
the fibrosis stage and of the inflammatory grade in chronic viral 
hepatitis.64 In this study by Colloredo and colleagues, the propor-
tion of biopsies showing at least bridging fibrosis was reduced 
from 41% in biopsies 30 mm x 1.4 mm to around 20% if the 
biopsy was as wide but 10 mm long, or 30 mm long but 1 mm 
wide. In another study, digital imaging was used to generate 
'virtual biopsies' from a grid superimposed on resection speci-
mens to find the size of biopsy required to reliably stage fibrosis. 
Modelling 2.5 mm increments 1 mm wide showed that a length 
of 25 mm was required to achieve a reproducible percentage area 
of fibrosis.66 The American Association for the Study of Liver 
Diseases (AASLD) position paper on liver biopsy recommends 
'long and wide (an ideal size is 3 cm long after formalin fixa-
tion obtained with a 16 G needle)'.6 Transjugular biopsies are 
indicated for patients with increased risk of complications (see 
section 'Morbidity and mortality') and/or when venous pressure 
studies are also required. Transjugular biopsy devices have a 
narrower gauge, usually 18–19G needles, and therefore require 
multiple passes. It has been shown that four passes are required 
for optimal specimens.190
Recently, FNA specimens from the liver obtained under endo-
scopic ultrasound guidance have been introduced. These are 
used in endoscopic biliary investigation for painful jaundice and 
generate narrow fragmented specimens which may be sufficient 
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to suggest the cause of jaundice (obstructive, hepatitic, late stage 
chronic disease) when no specific obstruction by stone or stric-
ture has been identified by the examination.134 191 FNA speci-
mens are not usually suitable for full histological assessment of 
diagnosis or disease stage.
Both side- cut and end- cut needles are widely used across the 
UK. There is little published evidence comparing the quality of 
biopsy samples obtained from different needles. The number of 
portal tracts in a given length of biopsy is variable and cannot 
be predicted from the biopsy length.67 76 A 16 G needle biopsy 
specimen was found to be intact significantly more often than 
with 18 G biopsy needles (71% compared with 24%) and to 
contain double the number of complete portal tracts per length 
of biopsy.76 Based on the above standard of an adequate biopsy 
being 20 mm in length and including >10 portal tracts, inade-
quate <10 mm and <6 portal tracts, with intermediate samples 
described as 'compromised', one audit showed an adequate rate 
of 24.7% and inadequate of 21.9% in biopsies between 2008 
and 2011, which represented a significant improvement on 
pre-2008 figures.68 This study corroborated the effect of biopsy 
size on fibrosis stage, with cirrhosis diagnosed in 6.5%, 11.0% 
and 14.6% of inadequate, compromised and adequate biopsies, 
respectively, while the proportion reported as no fibrosis was 
27.1%, 12.1% and 7.3%.
A second core may therefore be needed to provide sufficient 
biopsy tissue. There is concern that more than one pass for a 
medical liver biopsy increases the complication rate, although 
no clear evidence on this point exists.35 61 Pragmatically, a second 
pass should be considered if the biopsy core is <20 mm long and 
especially if the purpose of the biopsy is to investigate fibrosis 
stage or possible biliary disease.
The biopsy report should include both the length of the biopsy 
specimen, whether there is fragmentation and an approximate 
number of portal tracts. This gives an objective measure of the 
reliability of the sample.10 Some biopsy interpretation is possible 
even if the amount of liver tissue is small, but the pathologist 
should state in their report that the biopsy is too small to provide 
a full assessment of the liver disease.
handling of biopsy
Routine needle core or wedge biopsies are submitted in formalin 
and are best sent free- floating rather than attached to blotting 
paper. Biopsies from patients with known risk of infection, 
including hepatitis B and C viruses, HIV and tuberculosis should 
be labelled according to the local generic policy for specimens 
with a danger of causing infection; in view of the small specimen 
size, needle core biopsies do not require additional time in fixa-
tive before processing.
Requests for fresh tissue sent for immediate frozen section 
analysis must be communicated in advance with the labora-
tory, with clear indications of the findings and procedures being 
undertaken. These will generally be biopsies of subcapsular 
lesions and sent as small wedges of tissue.
If the clinical differential diagnosis includes Wilson’s disease, 
a separate core of tissue should be taken for copper estimation 
by the chemical pathology department; this should be wrapped 
in moistened paper, but not floating in formalin or saline. The 
same process would be used for iron content, but this is now 
rarely required. If the clinical diagnosis includes acute fatty liver 
of pregnancy, the liver biopsy should be sent fresh for frozen 
section for fat, since microvesicular steatosis in that condition 
may not be visible in fixed paraffin sections. Fresh samples for 
fat and freezing for metabolic disease may also be taken from 
paediatric patients; this is outside the scope of these guidelines. 
If a focal infective lesion/abscess is suspected, an additional fresh 
sample may also be sent to microbiology.
Detailed guidance for the processing, staining and reporting 
of liver biopsies is available in the Royal College of Pathologists 
'Tissue pathways for liver biopsies' document.10
Communication between clinician and pathologist
Information from clinician to pathologist
It is essential that the clinical indication/purpose for the biopsy 
is communicated to the reporting pathologist on the biopsy 
request form, to enable provision of a clinically useful report.
It must be clearly stated whether the biopsy is from a focal 
lesion or is non- targeted, obtained for investigation of diffuse 
liver disease; these two types of biopsy are handled differently 
in the laboratory so it is important that the staff who receive the 
biopsy are aware of its nature and ensure appropriate handling.
Results of relevant clinical investigations (including biochem-
istry, immunology and imaging, as appropriate) and a note of 
any previous liver biopsies should also be provided.
Pathologists often obtain additional clinical information from 
the electronic patient record, but the primary indication for biopsy 
may be obscured among a mass of information and should always 
be clearly specified on the request form. Furthermore, the biopsy 
may not be reported in the same institution as it was taken, so the 
additional source of information may not be available.
Communication of findings
For the primary reporting of medical liver biopsies, the reporting 
style and order of items included in the report are influenced by 
personal preference of the reporting pathologist/clinician. Items 
that are recommended to be included in all medical liver biopsy 
reports are listed in box 3. Where appropriate, recognised scoring 
systems should be used (see online supplementary appendix).
pathology reporting
Liver biopsies are received by most pathology departments in 
the UK and elsewhere. The Royal College of Pathologists tissue 
pathways document recommends that biopsies are reported by 
pathologists who have sufficient knowledge of hepatology to 
formulate a report that deals with the clinical question. Outside 
hepatology centres, it is recommended that there is a local lead 
histopathologist responsible for liver biopsies, and that the 
reporting pathologists work in close communication with local 
clinicians, ideally by a regular clinicopathological conference. 
This helps to maintain their expertise and to identify biop-
sies and cases which may benefit from a second opinion. They 
should have time for regular continuous professional develop-
ment activity in liver pathology, and at least one member of the 
department should undertake some form of external quality 
assurance in liver pathology. When late post- transplant biopsies 
are taken in the patient’s local hospital, it is recommended that 
these are referred to the relevant transplant centre for review.
For pathologists working in hepatology centres, there should be 
at least two consultants with specialist interest in liver pathology 
to ensure adequate cover, to support a regular clinical meeting 
for biopsy discussion and provide a referral service within the 
hepatology network. For transplant centres, a review service for 
transplant biopsies taken elsewhere should be provided.
There have been studies of circumstances when the original 
diagnosis on a liver biopsy is amended through specialist review 
as a result of clinical referral. Bejarano found major discrepancy 
in 28% that would affect management, and minor discrepancy 
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box 3 Guide to the content of a histopathology report
Clinical information received with the biopsy— including the 
indication/purpose of the biopsy. It is also useful to summarise 
any additional information available to the pathologist prior to 
the time of reporting, including information obtained from the 
electronic patient record and clinical discussion as appropriate.
Biopsy size/adequacy—expressed as length of biopsy core 
(on receipt in the department or on the tissue sections), number 
of fragments and an approximate number of portal tracts per 
section—to give an objective indication of the specimen quality.
Architecture—presence and severity of fibrosis, distortion of 
hepatocyte plates and vascular relationships, and parenchymal 
nodularity, as an indication of whether there is any chronic liver 
disease, if so whether there is bridging fibrosis or cirrhosis.
A systematic description of the histological abnormalities, 
including special stain findings (even when these are negative).
For medical liver biopsies an attempt should be made 
whenever possible to provide an indication of the main 
morphological pattern of liver disease.
Where appropriate (especially chronic liver disease) an 
indication of the severity of disease in terms of grade/stage. This 
can be by descriptive text or use of a scoring system appropriate 
to the disease, as preferred by local clinical practice.
Comparison with any previous liver biopsies, especially if the 
purpose of the biopsy is to investigate disease progression, or 
response to treatment.
A clinicopathological comment, including a note of any 
discussion with the responsible clinician. A concise, single line 
summary to conclude the report.
A SNOMED- CT code*
A record (including names) of any intradepartmental 
consultation, outside referral for second opinion and/
or discussion with clinician, if necessary, this may be as a 
supplementary report
*(SNOMED (Synchronised Nomenclature in Medicine) is a recognised 
structural vocabulary for use in an electronic clinical record.196
in 37% biopsies; interpretation errors were the most common 
for chronic cholestatic disease and cirrhosis.192 More recently, 
Paterson found a discrepancy in 59% of reviewed cases, although 
this included those sent for a second opinion as well as clinical 
referral, again with biliary disease as the the most common type 
of discrepancy and also highlighting issues with autoimmune 
disease and vascular abnormalities. A detailed clinical review 
found 61% of discrepancies affected clinical management.193 A 
third review found a discrepancy rate of 38% with 70% (26% of 
all referred cases) assessed as having a major clinical impact.194
Many specialist groups and societies give advice on when to 
take a liver biopsy in various disease categories and awareness of 
these guidelines will help pathologists in constructing relevant 
reports (see online supplementary appendix A). It is strongly 
suggested that because of the challenges in diagnosis and also 
management implications, specialist review should be consid-
ered in new diagnoses of autoimmune disease, problematic 
biliary disease, including overlap entities and suspected vascular 
diseases, as a matter of routine.
Timeliness of report
For routine, non- urgent biopsies, it is recommended that cases 
are reported and authorised within 10 days of the biopsy being 
taken. However, variance from this may be appropriate so that 
all investigations can be completed and there has been an oppor-
tunity for clinicopathological discussion or if the biopsy has 
been referred elsewhere for reporting; an interim report may be 
issued in such circumstances.
For diagnostic biopsies where the report is required more 
urgently (eg, acute liver failure, transplant biopsies) a preliminary 
report should be given by telephone or email; the diagnosis and 
time/date of the provisional report, including a summary of any 
clinico- pathological discussion, should be recorded in the final 
report.
Long term storage of biopsy specimens
Review of previous biopsy material, sometimes going back over 
many years, can provide important information concerning the 
progression of liver disease, or of the nature of liver disease in a 
relative of a patient who may have an inherited disorder. Tissue 
blocks and glass microscope slides of tissue samples from living 
patients are normally stored for at least 30 years. If a shorter 
time is being considered, then blocks that provided the basis of 
a diagnosis of rare diseases or inherited genetic predisposition 
should be considered for permanent retention. In practice, it 
would be extremely laborious to select such material, and the 
histology archive is generally preserved for 30 years.195
Recommendations
 ► The clinical indication for liver biopsy should be clearly 
communicated to the reporting pathologist by the requesting 
clinician (strength of recommendation STRONG; evidence 
HIGH).
 ► It must be clearly indicated if the biopsy is targeted at a focal 
lesion (‘tumour biopsy’) or taken for investigation of diffuse 
parenchymal disease (‘medical liver biopsy’) (strength of 
recommendation STRONG; evidence HIGH).
 ► For percutaneous medical liver biopsy, the specimen should 
be obtained with a 16 G needle and measure >20 mm in 
order to provide adequate tissue for examination. Consider 
a second pass if a smaller specimen is obtained, especially 
for investigation of fibrosis stage or possible biliary disease 
(strength of recommendation MODERATE; evidence HIGH).
 ► For targeted biopsy from a focal lesion, an 18 G needle is 
recommended; we recommend that an additional biopsy 
is obtained from the non- lesional tissue (not adjacent to 
the lesion) to evaluate background liver disease and can be 
done using the same needle (strength of recommendation 
STRONG; evidence HIGH)
 ► We recommend that for transjugular biopsies, at least two 
biopsies are taken (strength of recommendation STRONG; 
quality of evidence HIGH).
 ► The biopsy report should clearly deal with the clinical indi-
cation for the biopsy and conclude with a concise diagnostic 
summary (strength of recommendation STRONG; quality of 
evidence HIGH).
 ► For biopsies obtained outside a specialist liver centre, we 
recommend that the reporting pathologist should have 
access to second opinion from a liver centre (strength of 
recommendation STRONG; quality of evidence HIGH).
profEssionAL rEsponsibiLiTy
The clinical decision to do a liver biopsy, to conduct the biopsy, 
process, analyse the sample and interpret it in the clinical 
context, to relay the report to the patient and make a manage-
ment decision jointly with the patient is a complex process 
involving a number of clinicians with different specialist skills. 
The procedure itself has its own risks, but errors in other steps 
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in this process can lead to the wrong diagnosis or management 
decision and has the potential to cause significant harm.
Many healthcare professionals are involved in the liver biopsy 
process so establishing clear accountability can be challenging. Each 
member of the team is accountable for the part they play. Clear 
communication of all relevant information is vital to the process. 
This may be difficult when those involved are in different loca-
tions. It is essential that the practitioners have access to all current 
relevant information. The practitioner obtaining the biopsy must 
be informed when new information becomes available that may 
alter the risk/benefit balance of the biopsy. The decision to obtain 
a liver biopsy involves balancing the risks of the procedure with 
the benefits gained; it should be noted that the operator, if not the 
responsible clinician, may not be in a position fully to assess the 
benefits and must rely on the advice of the clinician requesting the 
biopsy.
Hospitals and teams involved in the liver biopsy service 
should have internal clinical governance in place to audit and 
improve their quality and participate in external quality assur-
ance and improvement programmes such as the Royal College of 
Physicians accreditation of liver units iQUILS (improvement of 
Quality In Liver Services) adopted in England and Wales.
Recommendation
 ► All members of the team involved in the clinical decision- 
making related to obtaining a liver biopsy should be aware 
of the risks and the benefit in each individual case, and 
hospitals must facilitate multidisciplinary and collaborative 
working as well as clinical quality assurance and improve-
ment (strength of recommendation STRONG; evidence 
HIGH).
 ► Serious complications including bile leakage, severe pain 
requiring additional hospitalisation, significant bleed 
requiring blood transfusion and death should be monitored 
on a local level (strength of recommendation STRONG; 
evidence WEAK).
fuTurE rEsEArCh
Liver biopsy remains an important tool in the diagnosis and 
management of patients with abnormalities of liver tests and occa-
sionally, in systemic disease; there is a small but significant risk of 
harm and even death. Newer technologies, such as incorporation 
of sensor arrays in the tip of biopsy needles (PMID: 31 698 304), 
may allow yet more information to be derived from a liver biopsy.
Audit
As practice is changing with the development of new diagnostic 
tests and investigations, and with new methodologies and tech-
nologies, lessons learnt from the past may be less relevant for 
providing informed consent. We suggest that
 ► There should be agreed standards nationally and interna-
tionally for the definitions of adverse effects.
 ► Both hospitals and professional organisations should 
conduct periodic audits of practice and outcomes; profes-
sional organisations should set up national databases for 
significant adverse events.
Training and competencies
 ► We recommend that there should be clear guidance for the 
establishment of competence for liver biopsy with respect 
both to training and current practice.
Coagulation and bleeding
As more is understood about the causes of bleeding after liver 
biopsy, we suggest that more research is required to
 ► Develop the most appropriate measure(s) of the risk of 
bleeding.
 ► Agree the safest way of managing a patient’s need for 
ongoing anticoagulation or antiplatelet therapy and liver 
biopsy.
biopsy needles
Technologies for taking liver specimens are improving and new 
needles are being introduced.
 ► We recommend that there should be more comparative 
audits that compare the efficacy of different needles with 
respect to safety, adequacy of specimen and cost.
QuALiTy sTAndArds
 ► For non- urgent biopsies, the interval between request and 
biopsy should be less than 4 weeks, irrespective of approach 
(percutaneous, transvenous or other).
 ► All patients should be given oral and written information 
about the indication, benefits and risk of biopsy and details 
of post- discharge support.
 ► Percutaneous biopsies should be obtained using a 16 G 
needle (except for lesional biopsies for which an 18 G needle 
is recommended).
 ► A provisional report for non- urgent biopsies will normally 
be given within 10 days of biopsy.
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